Keane, William F.

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine

Chronic Kidney Disease and DiabetesRenin-Angiotensin System Studies

Cited by 7,493

The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study

Keane, W. F., Brenner, B. M., de Zeeuw, D., Grunfeld, J.-P., McGill, J., Mitch, W. E., Ribeiro, A. B., Shahinfar, S., Simpson, R. L., Snapinn, S. M., et al. (2003) · Kidney International

Chronic Kidney Disease and DiabetesAcute Kidney Injury Research

Cited by 539

Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials

Heerspink, H. J. L., Greene, T., Tighiouart, H., Gansevoort, R. T., Coresh, J., Simon, A. L., Chan, T. M., Hou, F. F., Lewis, J. B., Locatelli, F., et al. (2019) · The Lancet Diabetes & Endocrinology

Chronic Kidney Disease and DiabetesStatistical Methods in Clinical Trials

Cited by 397

Effects of MAT9001 containing eicosapentaenoic acid and docosapentaenoic acid, compared to eicosapentaenoic acid ethyl esters, on triglycerides, lipoprotein cholesterol, and related variables

Maki, K. C., Bobotas, G., Dicklin, M. R., Huebner, M., & Keane, W. F. (2017) · Journal of Clinical Lipidology

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 20

Pharmacokinetics of MAT9001, an Omega‐3 Fatty Acid Medication, Compared with Eicosapentaenoic Acid Ethyl Esters in Hypertriglyceridemic Subjects

Maki, K. C., Keane, W. F., Bouhajib, M., Pop, R., & Bobotas, G. (2016) · The FASEB Journal

Fatty Acid Research and HealthLipid metabolism and disorders

Cited by 6